Captrust Financial Advisors Invests $997,000 in Core Laboratories Inc. (NYSE:CLB)

Captrust Financial Advisors purchased a new stake in shares of Core Laboratories Inc. (NYSE:CLB - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 53,799 shares of the oil and gas company's stock, valued at approximately $997,000. Captrust Financial Advisors owned approximately 0.11% of Core Laboratories as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of CLB. Disciplined Growth Investors Inc. MN increased its holdings in Core Laboratories by 446.8% in the second quarter. Disciplined Growth Investors Inc. MN now owns 4,460,720 shares of the oil and gas company's stock worth $90,508,000 after buying an additional 3,644,963 shares during the last quarter. Earnest Partners LLC raised its holdings in shares of Core Laboratories by 6.3% during the 2nd quarter. Earnest Partners LLC now owns 3,286,438 shares of the oil and gas company's stock valued at $66,682,000 after purchasing an additional 195,756 shares in the last quarter. Royce & Associates LP raised its holdings in shares of Core Laboratories by 9.0% during the 3rd quarter. Royce & Associates LP now owns 1,021,121 shares of the oil and gas company's stock valued at $18,921,000 after purchasing an additional 84,022 shares in the last quarter. Fisher Asset Management LLC lifted its stake in shares of Core Laboratories by 19.5% in the 3rd quarter. Fisher Asset Management LLC now owns 990,267 shares of the oil and gas company's stock valued at $18,350,000 after purchasing an additional 161,278 shares during the last quarter. Finally, Boston Trust Walden Corp boosted its holdings in Core Laboratories by 1.3% in the second quarter. Boston Trust Walden Corp now owns 729,760 shares of the oil and gas company's stock worth $14,807,000 after purchasing an additional 9,468 shares in the last quarter. 97.81% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. StockNews.com raised Core Laboratories from a "sell" rating to a "hold" rating in a research report on Thursday, November 7th. Citigroup reduced their price objective on Core Laboratories from $15.00 to $14.00 and set a "sell" rating for the company in a research report on Thursday, October 31st. Two analysts have rated the stock with a sell rating and three have given a hold rating to the stock. Based on data from MarketBeat.com, Core Laboratories presently has a consensus rating of "Hold" and an average target price of $17.00.

Core Laboratories Price Performance

Shares of CLB traded up $0.14 during trading hours on Tuesday, hitting $19.53. The stock had a trading volume of 235,517 shares, compared to its average volume of 412,672. The stock has a market capitalization of $916.93 million, a price-to-earnings ratio of 30.05, a P/E/G ratio of 1.30 and a beta of 2.35. Core Laboratories Inc. has a 52 week low of $13.82 and a 52 week high of $25.13. The company's fifty day moving average is $19.68 and its two-hundred day moving average is $19.66. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.48 and a quick ratio of 1.79.

Core Laboratories (NYSE:CLB - Get Free Report) last issued its quarterly earnings data on Wednesday, October 23rd. The oil and gas company reported $0.25 EPS for the quarter, topping analysts' consensus estimates of $0.21 by $0.04. Core Laboratories had a net margin of 5.83% and a return on equity of 15.84%. The firm had revenue of $134.40 million for the quarter, compared to analyst estimates of $134.16 million. During the same quarter in the prior year, the firm earned $0.22 EPS. The company's revenue was up 7.2% on a year-over-year basis. On average, analysts anticipate that Core Laboratories Inc. will post 0.8 EPS for the current year.

Core Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 25th. Investors of record on Monday, November 4th were given a $0.01 dividend. This represents a $0.04 annualized dividend and a yield of 0.20%. The ex-dividend date of this dividend was Monday, November 4th. Core Laboratories's dividend payout ratio (DPR) is presently 6.15%.

About Core Laboratories

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.